Zevra Therapeutics

Zevra Therapeutics is a company listed under the stock ticker KMPH (US).

View the org chart displaying its 18 main executives

Most searched biographies at Zevra Therapeutics

• Richard Pascoe, Chief Executive Officer
• Joseph Saluri, Director
• Matthew Plooster, Chairman of the Board

Popular executive movements at Zevra Therapeutics

• Daniel Gallo has joined the company as Senior Vice President of Medical Affairs and Advocacy  (posted on January 31 2023).
• Abbi Maher has joined the company as Vice President of Legal Affairs  (posted on January 31 2023).
• Sven Guenther, who was Executive Vice President of Research & Development, is promoted to Chief Scientific Officer  (posted on January 11 2023).

Click here to view some more movements at Zevra Therapeutics

Create your alert
to follow the executive moves at Zevra Therapeutics.

Zevra Therapeutics has 1,926 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland).

Popular M&A news in Pharmaceuticals

• Ambrx has just announced a $78 Million fundraising (posted on March 13 2023).
• Mayne Pharma US and Dr. Reddy's have announced they will merge  (posted on February 28 2023)..
• Fusion Pharma has just announced a $60 Million fundraising (posted on February 16 2023).

Popular contacts in Pharmaceuticals

• Danilo Cicmil - Supervisory Board Member at Galenika
• Stéphane Bancel - Director, President and Founding Chief Executive Officer at Moderna
• Rongrong Pan - Vice President and Chief Financial Officer at Sciclone Pharmaceuticals

Learn more about the Pharmaceuticals industry >

Press releases by Zevra Therapeutics

• KemPharm to Report Second Quarter 2022 Financial Results | KemPharm
• KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference | KemPharm
• KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting | KemPharm
• KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion | KemPharm
• Press Releases | KemPharm
• KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline | KemPharm
• KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates | KemPharm
• Press Releases | KemPharm
• KemPharm to Present at Multiple Upcoming Investor Conferences | KemPharm
• KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) | KemPharm
• View more press releases Close

Social media about Zevra Therapeutics

• Zevra Therapeutics on Wikipedia, Google News & Yahoo Finance
• Zevra Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Richard Pascoe

Call Zevra Therapeutics at +1 319...

View the org chart

Register to receive your alert

Report an error